Exact Sciences Reports Q4 Revenue Growth, Plans New Cancer Tests

Exact Sciences Corporation reported a fourth-quarter revenue of $713.42 million, exceeding the Zacks Consensus Estimate by a slight margin and reflecting a year-over-year increase. The company posted a non-GAAP loss of $0.06 per share, significantly better than the anticipated loss of $0.32, marking an 81.25% earnings surprise. For the full fiscal year, Exact Sciences generated total revenues of $2.76 billion, driven by increased adoption of its Cologuard and Oncotype DX tests. Looking ahead, the company plans to launch three new diagnostic tests in 2025 and expects revenue growth to continue, projecting an annual revenue of around $3.06 billion for the upcoming year. Despite recent successes, the company has faced challenges including significant operational losses and rising competition in the molecular diagnostics field. Investors are keen to see how management will navigate these hurdles and capitalize on growth opportunities in the future.